Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Acquires $49,983.22 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) Director Michael Houghton acquired 3,202 shares of the stock in a transaction dated Monday, December 30th. The stock was bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the purchase, the director now directly owns 3,202 shares in the company, valued at approximately $49,983.22. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Assembly Biosciences Price Performance

ASMB traded down $0.25 during trading hours on Tuesday, reaching $15.78. 26,979 shares of the company's stock traded hands, compared to its average volume of 25,531. The firm has a 50-day moving average price of $16.02 and a 200 day moving average price of $15.60. Assembly Biosciences, Inc. has a 52-week low of $9.12 and a 52-week high of $19.93.

Analyst Ratings Changes

Several brokerages have recently weighed in on ASMB. Jefferies Financial Group raised shares of Assembly Biosciences from a "hold" rating to a "buy" rating and increased their target price for the company from $2.00 to $35.00 in a research note on Friday, September 20th. HC Wainwright reissued a "neutral" rating on shares of Assembly Biosciences in a research report on Friday.

Institutional Trading of Assembly Biosciences

A number of large investors have recently made changes to their positions in ASMB. JPMorgan Chase & Co. lifted its holdings in Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 3,442 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company's stock valued at $184,000 after acquiring an additional 7,690 shares in the last quarter. FMR LLC raised its stake in shares of Assembly Biosciences by 29.7% during the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company's stock valued at $240,000 after acquiring an additional 3,635 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company's stock valued at $753,000 after purchasing an additional 15,451 shares during the period. Finally, Armistice Capital LLC bought a new position in Assembly Biosciences in the second quarter worth approximately $6,421,000. 19.92% of the stock is owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.